News - Zaltrap, Vectibix

Filter

Current filters:

ZaltrapVectibix

Popular Filters

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

Regeneron revenues leap, boosted by stronger than expected sales of Eylea

11-02-2014

US biotech firm Regeneron Pharmaceuticals reports that its blockbuster ophthalmic drug Eylea (aflibercept)…

BayerBiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronResearchSanofiZaltrap

Amgen and Illumina to develop companion diagnostic for Vectibix

Amgen and Illumina to develop companion diagnostic for Vectibix

16-01-2014

USA-based Illumina has entered into an agreement with Amgen to develop and commercialize a multigene,…

AmgenBiotechnologyIlluminaOncologyResearchVectibix

Fast growth forecast for China’s colorectal cancer market

Fast growth forecast for China’s colorectal cancer market

13-12-2013

From 2012 to 2017, the colorectal cancer therapy market in China will grow at an annual rate of 9%, from…

AmgenAsia-PacificBayerIndiaMarkets & MarketingOncologyPharmaceuticalSanofiStivargaVectibixZaltrap

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

US and European Rxing decisions on metastatic colorectal cancer

15-07-2013

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

AvastinBayerEli LillyEuropeMarkets & MarketingNorth AmericaOncologyPharmaceuticalramucirumabRegeneronRocheSanofiStivargaZaltrap

UK's NICE issues negative new draft guidance on Sanofi's Zaltrap

21-06-2013

The UK's drug watchdog the National Institute for Health Care and Excellence (NICE) has issued new draft…

EuropeOncologyPharmaceuticalPricingRegulationSanofiZaltrap

Regeneron posts strong growth for 2012, beating analysts' estimates

15-02-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were…

BiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronZaltrap

Sanofi's Zaltrap gets EU approval for metastatic colorectal cancer

06-02-2013

In a second European approval within a matter of days, French drug major Sanofi (Euronext: SAN) said…

EuropeOncologyPharmaceuticalRegeneronRegulationSanofiZaltrap

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene

19-11-2012

There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…

BexseroBiotechnologyCelgeneDiabetesEuropeIstodaxLyxumiaNovartisOncologyPharmaceuticalRegulationSanofiVaccinesZaltrap

Sanofi halves US price of Zaltrap, responding to criticism from oncologists

12-11-2012

French drug major Sanofi (Euronext: SAN) has said that it would halve the price of its colorectal cancer…

North AmericaOncologyPharmaceuticalPricingSanofiZaltrap

Positive Ph III VELOUR results with Sanofi's Zaltrap

10-10-2012

French drug major Sanofi (Euronext: SAN) says that positive detailed results from the pivotal Phase III…

OncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Zaltrap gains US approval for metastatic colorectal cancer

06-08-2012

The US Food and Drug Administration on Friday approved French drug major Sanofi (Euronext: SAN) and US…

North AmericaOncologyPharmaceuticalRegeneronRegulationSanofiZaltrap

Sanofi and Regeneron mCRC drug Zaltrap misses goals but gets FDA priority

10-04-2012

The US Food and Drug Administration has granted priority review of the Biologics License Application…

BiotechnologyNorth AmericaPharmaceuticalRegeneronRegulationResearchSanofiZaltrap

UK’s NICE negative draft guidance for metastatic colorectal cancer drugs Erbitux, Avastin and Vectibix

06-09-2011

In new draft guidance issued this week, UK drug watchdog the National Institute for Health and Clinical…

AmgenAvastinErbituxEuropeMerck KGaAOncologyPharmaceuticalPricingRegulationRocheVectibix

Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival

07-06-2011

French drug major Sanofi (Euronext: SAN) announced results at the American Society of Clinical Oncology…

Cardio-vascularGastro-intestinalsOncologyPharmaceuticalRegeneronResearchSanofisemuloparinZaltrap

Sanofi-Aventis and Regeneron’s Zaltrap improves OS in Ph III colon cancer study

28-04-2011

French drug major Sanofi-Aventis (Euronext: SAN) and USA-based partner Regeneron Pharmaceuticals (Nasdaq:…

afliberceptOncologyPharmaceuticalRegeneronResearchSanofi-AventisZaltrap

Back to top